Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2009. The report serves as a notification to the market regarding the company's issued share capital and total voting rights as of August 31, 2009, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the specific composition of the company's share capital as of August 31, 2009:
- Total issued ordinary shares: 5,662,741,873 (25p each).
- Shares held in Treasury: 474,194,158.
- Total voting rights: 5,188,547,715.
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of voting rights to assist shareholders in determining notification requirements under the Financial Services Authority's rules.
Investor Verification Checklist
- Verify the total number of voting rights (5,188,547,715) against the company's latest annual report to confirm the denominator for disclosure thresholds.
- Confirm the number of treasury shares (474,194,158) to understand the difference between issued capital and voting capital.
- Check subsequent filings for any changes in share capital or treasury holdings since August 31, 2009.